Medicinal and edible composition capable of improving blood vessel state

Abstract

According to the composition capable of improving the blood vessel state provided by the invention, medicinal and edible food raw materials are reasonably combined, and natto powder with high nattokinase content is selected and matched with ginseng, isomaltooligosacharide, oat beta-glucan and the like. Animal experiments show that the whole formula has a synergistic promotion effect on reducing blood fat, improving blood flow and the like, and particularly, ginseng, enough isomaltooligosacharide and oat beta glucan have a remarkable influence on the effect of improving the blood vessel state.

Description

Technical Field

[0003] The invention relates to a medicine-food homologous composition capable of improving blood vessel status, and belongs to the technical field of food. Background Art

[0005] A healthy vascular system can ensure the normal circulation of blood, provide sufficient oxygen and nutrients to various organs of the body, and effectively remove metabolites and waste. Therefore, the healthy maintenance of blood vessels is an important part of maintaining overall physical health. Commonly used vascular maintenance ingredients include statins, non-steroidal anti-inflammatory drugs, clopidogrel and other Western medicine antiplatelet ingredients, as well as traditional ingredients rich in antioxidants, such as fish, grapes, green tea and nuts. In recent years, natto products that have emerged from Japan have also gradually been valued. At present, there are many types of natto products in the domestic market, but there are few products with good quality and reputation. Summary of the invention

[0007] The purpose of the present invention is to provide a medicine-food combination having the function of improving blood vessel status, which is mainly prepared by using a medicine-food combination of prebiotics, hawthorn, ginseng, natto powder and the like.

[0008] The technical scheme of the present invention is as follows: a medicine and food composition for improving vascular status, comprising the following raw materials in parts by weight: 60-90 parts of isomaltooligosaccharide, 60-90 parts of hawthorn powder, 60-90 parts of ginseng powder, 40-70 parts of oat beta-glucan, 40-70 parts of natto powder, 40-70 parts of bamboo leaf flavonoids, 10-30 parts of red yeast rice, and 10-30 parts of sea buckthorn powder.

[0009] Preferably, the above-mentioned edible and medicinal composition for improving vascular status comprises the following raw materials in parts by weight: 80 parts of isomaltooligosaccharide, 66 parts of hawthorn powder, 62 parts of ginseng powder, 55 parts of oat β-glucan, 50 parts of natto powder, 45 parts of bamboo leaf flavonoids, 20 parts of red yeast rice, and 15 parts of sea buckthorn powder.

[0010] Preferably, the present invention provides a medicine-food composition for improving vascular status, which is made of the following raw materials in parts by weight: 80 parts of isomaltooligosaccharide, 66 parts of hawthorn powder, 62 parts of ginseng powder, 62 parts of pregelatinized starch, 55 parts of oat β-glucan, 50 parts of natto powder, 45 parts of bamboo leaf flavonoids, 37 parts of sorbitol, 20 parts of red yeast rice, 15 parts of sea buckthorn powder, 5 parts of silicon dioxide, and 3 parts of magnesium stearate.

[0011] The present invention is preferably a medicine-food composition having the function of improving blood vessel status, wherein the nattokinase content in the natto powder is greater than or equal to 30,000 FU / g.

[0012] The preferred embodiment of the present invention is a medicine-food composition having the function of improving blood vessel status, wherein the improvement of blood vessel status includes the function of assisting in lowering blood lipids and improving blood flow.

[0013] The present invention is again preferably a medicine-food composition having the function of improving blood vessel status, wherein the improvement of blood vessel status includes auxiliary lipid-lowering effect and blood flow improvement effect; wherein the auxiliary lipid-lowering effect is specifically manifested in reducing triglyceride content and cholesterol content; wherein the blood flow improvement effect is specifically manifested in increasing blood vessel diameter, increasing blood flow velocity and increasing cardiac red blood cell staining intensity.

[0014] In the present invention, hawthorn is a traditional medicinal material used as both medicine and food, contains rich flavonoids, hawthorn acid and vitamin C, etc., has a strong antioxidant effect, can prevent free radicals from damaging vascular endothelial cells, and thus protect blood vessels.

[0015] Ginseng is a precious medicinal plant, suitable for regulating blood pressure, restoring heart function, neurasthenia and physical weakness, and also has the effects of expectoration, stomachic, diuretic, excitement, etc. Modern medicine believes that ginseng has obvious effects on the nervous system, cardiovascular system, endocrine system, digestive system, reproductive system, respiratory system and surgical use.

[0016] Oat β-glucan is a new food ingredient and a water-soluble dietary fiber that has the functions of regulating intestinal function, promoting digestion, etc. It helps control the absorption and distribution of blood sugar and blood lipids and maintain blood vessels.

[0017] Natto powder is a new food raw material, containing nattokinase and rich flavonoids. Nattokinase is a protein kinase, which also has a strong degradation effect on human thrombus protein. According to research, taking 2000FU of nattokinase daily can dissolve blood clots. The nattokinase content of the natto powder selected by the present invention is 40,000 FU / g.

[0018] Bamboo leaf flavonoids is a new food raw material with antioxidant, antibacterial, anti-inflammatory, lipid-lowering, anti-aging, anti-radiation, eye protection, and blood vessel protection effects.

[0019] Seabuckthorn is a plant unique to the plateau. Its fruit contains a large amount of flavonoids and multiple vitamins, and is known as the "king of vitamin C". Seabuckthorn has the effects of relieving cough and reducing phlegm, strengthening the stomach and digestion, and promoting blood circulation and removing blood stasis. Modern medical research shows that seabuckthorn can lower cholesterol, relieve angina attacks, and prevent and treat coronary artery atherosclerosis.

[0020] Red yeast rice is made by using red yeast rice fermentation technology to highly enrich the monaline K (equivalent to lovastatin) in the red yeast rice, fully exerting its antioxidant, blood vessel softening, and lipid-lowering effects, and further enhancing its anti-thrombotic ability.

[0021] Beneficial effects:

[0022] The present invention provides a composition capable of improving the state of blood vessels. The composition adopts a reasonable combination of food raw materials having the same origin as medicine, and has an obvious synergistic promoting effect by selecting natto powder with a high nattokinase content and combining it with ginseng and oat beta-glucan, etc., and can significantly improve the state of blood vessels, specifically, the auxiliary effect of lowering blood lipids and improving blood flow. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 to Figure 3 These are images and data obtained from the triglyceride-lowering experiment; Figures 4 to 6 To assist in the cholesterol-lowering experiment, images and data were obtained; Figure 7 to Figure 9 To improve the images and data obtained from the zebrafish tail fin blood vessel diameter experiment; Fig.10 This is a bar graph of zebrafish blood flow velocity after each sample treatment; Figure 11 to Figure 13 Images and data obtained from an experiment to improve blood flow to the heart.

[0025] in

[0026] Figure 1 Schematic diagram of the location of blood vessel analysis in the zebrafish tail (highlighted part below the tail fin); Figure 2 Typical images of blood vessel staining intensity in the tail of zebrafish after treatment of each group of samples; Figure 3 This is a bar graph of the zebrafish tail vascular staining intensity data after each group of sample treatment. The horizontal axis is each sample group, and the vertical axis is the fluorescence intensity (pixel).

[0027] Figure 4 Schematic diagram of the analysis of cholesterol fluorescence intensity in zebrafish tail blood vessels (the highlighted dotted part of the tail fin is the analysis site); Figure 5 This is a typical graph of cholesterol fluorescence intensity in zebrafish tail blood vessels after treatment of each group of samples; Figure 6 This is a bar graph of the cholesterol fluorescence intensity data in the zebrafish tail blood vessels after each group of sample treatment. The horizontal axis is each sample group, and the vertical axis is the fluorescence intensity (pixel).

[0028] Figure 7 Schematic diagram of zebrafish blood vessel diameter analysis (the dotted framed area is the analysis site); Figure 8 Typical diagrams of zebrafish blood vessel diameters after treatment of each sample (indicated by the highlighted opposing arrows); Fig. 9 This is a bar graph of zebrafish blood vessel diameter data after each sample treatment. The horizontal axis is each sample group, and the vertical axis is the blood vessel diameter (pixel).

[0029] Fig.11 Schematic diagram of zebrafish heart red blood cell staining intensity analysis (the dotted line indicated by the arrow is the analysis site); Fig.12Typical images of zebrafish heart red blood cell staining intensity after each sample treatment (indicated by the highlighted opposite arrows); Fig.13 The data bar graph shows the zebrafish heart red blood cell staining intensity after each sample treatment. The horizontal axis represents each sample group, and the vertical axis represents the fluorescence intensity (pixel).

[0030] In each bar graph: ZC is the normal group, MX is the model group, ASPL is the aspirin group, DB1 is the ginseng negative group, DB2 is the oat glucan negative group, SYZ is the Tibetan Jinbao experimental group; compared with the model control group, *p<0.05, **p<0.01, ***p<0.001; compared with the experimental group, #p<0.05, ##p<0.01, ###p<0.001. DETAILED DESCRIPTION

[0032] The present invention is further described in detail in conjunction with the following specific examples, and the protection scope of the present invention is not limited to the following examples. The process, conditions, experimental methods, etc. for implementing the invention, except for the contents specifically mentioned below, are common knowledge and common common sense in the field, and the present invention has no special restrictions.

[0033] Example 1. A medicinal and edible composition with improved vascular status (tentative name: Tibetan Jinbao tablet candy) is made of raw materials: 80g isomaltooligosaccharide, 66g hawthorn powder, 62g ginseng powder, 62g pregelatinized starch, 55g oat β-glucan, 50g natto powder, 45g bamboo leaf flavonoids, 37g sorbitol, 20g red yeast rice, 15g sea buckthorn powder, 5g silicon dioxide, 3g magnesium stearate. The nattokinase content in natto powder is 40,000 FU / g. The above raw materials are fully mixed and tableted in a tablet press. This sample was tested by a third party of the China Institute of Chemistry, and the nattokinase content was 3793FU / g. The sample was self-tested many times, and the nattokinase content was greater than 3000FU / g.

[0034] Example 2: A medicinal and edible composition for improving vascular status, made from the following raw materials (ginseng negative): 80g isomaltooligosaccharide, 66g hawthorn powder, 0g ginseng powder, 62g pregelatinized starch, 55g oat β-glucan, 50g natto powder, 45g bamboo leaf flavonoids, 37g sorbitol, 20g red yeast rice, 15g sea buckthorn powder, 5g silicon dioxide, 3g magnesium stearate. The nattokinase content in the natto powder is 40,000 FU / g. The above raw materials are fully mixed and tableted on a tablet press. The natto powder used in this sample is exactly the same as that in Example 1.

[0035] Example 3: A medicinal and edible composition for improving vascular status, made from the following raw materials (half isomaltooligosaccharide, negative oat β-glucan): 40g isomaltooligosaccharide, 66g hawthorn powder, 62g ginseng powder, 62g pregelatinized starch, 0g oat β-glucan, 50g natto powder, 45g bamboo leaf flavonoids, 37g sorbitol, 20g red yeast rice, 15g sea buckthorn powder, 5g silicon dioxide, 3g magnesium stearate. The nattokinase content in the natto powder is 40,000 FU / g. The above raw materials are fully mixed and tableted on a tablet press. The natto powder used in this sample is exactly the same as that in Example 1.

[0036] Example 4: A medicinal and edible composition for improving blood vessel status, comprising the following raw materials: 80g of isomaltooligosaccharide, 66g of hawthorn powder, 62g of ginseng powder, 55g of oat β-glucan, 50g of natto powder, 45g of bamboo leaf flavonoids, 20g of red yeast rice, and 15g of sea buckthorn powder. The nattokinase content in the natto powder is 30,000 FU / g.

[0037] Example 5: A medicinal and edible composition for improving blood vessel status, comprising the following raw materials: 60g of isomaltooligosaccharide, 60g of hawthorn powder, 60g of ginseng powder, 40g of oat β-glucan, 40g of natto powder, 40g of bamboo leaf flavonoids, 10g of red yeast rice, and 10g of sea buckthorn powder. The nattokinase content in the natto powder is 30,000 FU / g. The above raw materials are fully mixed and pressed into tablets on a tablet press.

[0038] Example 6: A medicinal and edible composition for improving blood vessel status, comprising the following raw materials: 90g of isomaltooligosaccharide, 90g of hawthorn powder, 90g of ginseng powder, 70g of oat β-glucan, 70g of natto powder, 70g of bamboo leaf flavonoids, 30g of red yeast rice, and 30g of sea buckthorn powder. The nattokinase content in the natto powder is 40,000 FU / g.

[0039] Example 7: A medicinal and edible composition for improving vascular status, comprising the following raw materials: 60 parts of isomaltooligosaccharide, 90 parts of hawthorn powder, 90 parts of ginseng powder, 40 parts of oat β-glucan, 40 parts of natto powder, 70 parts of bamboo leaf flavonoids, 10 parts of red yeast rice, and 30 parts of sea buckthorn powder.

[0040] Example 8: A medicinal and edible composition for improving vascular status, comprising the following raw materials: 90 parts of isomaltooligosaccharide, 90 parts of hawthorn powder, 60 parts of ginseng powder, 70 parts of oat β-glucan, 70 parts of natto powder, 40 parts of bamboo leaf flavonoids, 10 parts of red yeast rice, and 10 parts of sea buckthorn powder.

[0041] The following experimental examples were commissioned by a third party, Hangzhou Huante Biotechnology Co., Ltd., to conduct experiments to further illustrate the present invention, but do not constitute any limitation to the present invention.

[0042] Experimental Example 1: Auxiliary Effect of Lowering Blood Lipids

[0043] 1. Test materials

[0044] Sample preparation

[0045] The following samples were all prepared into 20.0 mg / mL stock solution with standard dilution water, diluted as needed, and used immediately after preparation. The samples in the experimental group were the Tibetan Jinbao tablet candy prepared in Example 1, the samples in the comparative group 1 were the ginseng negative control samples prepared in Example 2, and the samples in the comparative group 2 were the half-isomaltooligosaccharide and oat β-glucan negative samples prepared in Example 3.

[0046] Experimental animals

[0047] Zebrafish were kept in fish water at 28°C (water quality: 200 mg instant sea salt was added to 1 L of reverse osmosis water, conductivity was 450 ~ 550 µS / cm; pH was 6.5 ~ 8.5; hardness was 50 ~ 100 mg / L CaCO3), and the experimental animal use license number was: SYXK (Zhejiang) 2022-0004. The feeding and management complies with the requirements of the international AAALAC accreditation (accreditation number: 001458) and the IACUC ethics review number is: IACUC-2023-5749-01.

[0048] Wild-type AB strain zebrafish were bred in natural pairs. Zebrafish aged 5 days post fertilization (5 dpf) were used for the determination of the maximum detection concentration (MTC) of the lipid-lowering effect of Tibetan Jinbao tablet candy and its efficacy evaluation.

[0049] Instruments, consumables and reagents

[0050] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); precision electronic balance (CP214, OHAUS, USA); microinjection instrument (IM300, Narishige, Japan); needle puller (PC-10, Narishige, Japan); electric focus continuous zoom fluorescence microscope (AZ100, Nikon, Japan); 6-well plate (Zhejiang Bellanbo Biotechnology Co., Ltd., China).

[0051] Methylcellulose (lot number C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); 4% tissue cell fixative (lot number 20210828, Beijing Solebow Co., Ltd., China); Oil Red O (lot number SHBN4926, Sigma, USA); 1.2-propylene glycol (lot number 20211117, Sinopharm Chemical Reagent Co., Ltd., China); egg yolk powder (lot number 20230203, Zhejiang Aiger Biotechnology Co., Ltd., China); D-(+)-glucose (lot number I2209335, Shanghai Aladdin Biochemical Technology Co., Ltd., China); cholesterol BODIPY™ 542 / 563C11 (cholesterol probe, lot number 2291600, invitrogen, USA); dimethyl sulfoxide (DMSO, lot number BCCD8942, Sigma, Switzerland).

[0052] Detection Methods

[0053] MTC assay

[0054] 5 dpf wild-type AB strain zebrafish were randomly selected in beakers, and 30 zebrafish were treated in each beaker (experimental group). The Tibetan Jinbao tablet candy prepared in Example 1 was given in water (concentrations shown in Table 1), and a normal control group and a model control group were set up at the same time, with a capacity of 25 mL per cup. Except for the normal control group, the remaining experimental groups were given high-sugar and high-fat feed in water to establish a high-sugar and high-fat model of zebrafish. After 2 days of treatment at 28°C, the MTC of the Tibetan Jinbao tablet candy on the model zebrafish was determined.

[0055] Evaluation of the efficacy of assisting in lowering blood lipids (lowering triglycerides)

[0056] 5 dpf wild-type AB strain zebrafish were randomly selected in a beaker, and 30 zebrafish were treated in each beaker (experimental group). Three groups were set up, and the Tibetan Jinbao tablet candy prepared in Example 1-3 and two comparison samples of ginseng negative and oat glucan negative were respectively given in water, with a concentration of 62.5 μg / mL of MTC. A normal control group and a model control group were set up at the same time, and the capacity of each cup was 25 mL. Except for the normal control group, the remaining experimental groups were all given a high-sugar and high-fat feed in water to establish a high-sugar and high-fat model of zebrafish. After treatment at 28°C for 2 days, they were fixed with 4% tissue cell fixative, and oil red O was given for overall fat staining after fixation. After staining, 10 zebrafish were randomly selected from each experimental group and photographed under a dissecting microscope. The data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software, and the staining intensity of the zebrafish tail blood vessels was analyzed. The statistical analysis results of this indicator were used to evaluate the triglyceride-lowering effect of Tibetan Jinbao tablet candy. The statistical processing results are expressed as mean ± SE. SPSS 26.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant.

[0057] Evaluation of the efficacy of assisting in lowering blood lipids (lowering cholesterol)

[0058] 5 dpf wild-type AB strain zebrafish were randomly selected in a beaker, and 30 zebrafish were treated in each beaker (experimental group). Three groups were set up, and the Tibetan Jinbao tablet candy prepared in Example 1-3 and two comparison samples of ginseng negative and oat glucan negative were respectively given in water, with a concentration of 62.5 μg / mL of MTC. A normal control group and a model control group were set up at the same time, and the capacity of each cup was 25 mL. Except for the normal control group, the remaining experimental groups were all given high-sugar and high-fat feed in water to establish a high-sugar and high-fat model of zebrafish. After 1 day of treatment at 28°C, the cholesterol probe was injected. After 1 day of treatment, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. The data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software, and the cholesterol fluorescence intensity of the zebrafish tail blood vessels was analyzed. The statistical analysis results of this indicator were used to evaluate the cholesterol-lowering effect of Tibetan Jinbao tablet candy. The statistical processing results are expressed as mean ± SE. SPSS 26.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant.

[0059] Test results

[0060] MTC

[0061] Under the experimental conditions, the MTC of the auxiliary lipid-lowering effect of Tibetan Jinbao tablet candy is 62.5 μg / mL. See Table 1 for details.

[0062] Table 1 Results of the experimental study on the concentration of Zangdi Jinbao tablet candy in assisting in lowering blood lipids (n = 30)

[0063]

[0064] Evaluation of the efficacy of assisting in lowering blood lipids (lowering triglycerides)

[0065] Under the experimental conditions, Tibetan Jinbao tablet candy has a strong auxiliary effect in lowering triglycerides. The lack of ginseng (DB1), halving of isomaltooligosaccharide and the lack of oat glucan in the formula will significantly affect the triglyceride-lowering effect, indicating that ginseng has a very significant effect on the overall triglyceride-lowering effect of the formula, and the sufficient use of prebiotics (isomaltooligosaccharide, oat beta glucan) in the formula also has a significant effect on lowering triglycerides. See Table 2 for details. Figure 1 , Figure 2 and Figure 3 .

[0066] Table 2. Experimental results of the evaluation of the auxiliary lipid-lowering effect (triglyceride-lowering) of each group of samples (n = 10)

[0067] Group Concentration (μg / mL) Blood vessel staining intensity in the tail (pixels, mean ± SE) Normal control group (ZC) - 7585 ± 210*** Model control group (MX) - 30682 ± 1986 Comparison group 1 (DB1) 62.5 26309 ± 1153### Comparison Group 2 (DB2) 62.5 23747 ± 1359**# Experimental group (SYZ) 62.5 19264 ± 1375***

[0068] Compared with the model control group, **p < 0.01, ***p < 0.001; compared with the experimental group, #p < 0.05, ##p < 0.01, ###p < 0.001

[0069] Evaluation of the efficacy of assisting in lowering blood lipids (lowering cholesterol)

[0070] Under the experimental conditions, Tibetan Jinbao tablet candy has the effect of assisting in lowering cholesterol, and the absence of ginseng (DB1) in the formula will significantly affect the cholesterol-lowering effect. See Table 3 for details. Figure 4 , Figure 5 and Figure 6 .

[0071] Table 3. Results of the experimental evaluation of the auxiliary lipid-lowering effect (cholesterol-lowering) of each group of samples (n = 10)

[0072] Group Concentration (μg / mL) Cholesterol fluorescence intensity of tail blood vessels (pixels, mean ± SE) Normal control group (ZC) - 47848 ± 2598*** Model control group (MX) - 84728 ± 4716 Comparison group 1 (DB1) 62.5 52493 ± 3005***# Comparison Group 2 (DB2) 62.5 44760 ± 4334*** Experimental group (SYZ) 62.5 43653 ± 2741***

[0073] Compared with the model control group, **p < 0.01, ***p < 0.001; compared with the experimental group, #p < 0.05, ##p < 0.01, ###p < 0.001

[0074] Experimental Example 2: The effect of Tibetan Jinbao tablet candy on improving blood flow

[0075] 1. Test materials

[0076] Sample preparation information

[0077] The following samples were all prepared into 1.00 mg / mL stock solution with standard dilution water, diluted as needed, and used immediately after preparation. The samples in the experimental group were the Tibetan Jinbao tablet candy prepared in Example 1, the samples in the comparative group 1 were the ginseng negative control prepared in Example 2, and the samples in the comparative group 2 were the half-isomaltooligosaccharide and oat β-glucan negative samples prepared in Example 3.

[0078] Positive control: Enteric-coated aspirin tablets (hereinafter referred to as aspirin), white tablets, batch number BJ72163, Bayer Healthcare Co., Ltd., stored in a cool place. Prepared into a 60.0 mg / mL stock solution with DMSO and stored at -20 °C.

[0079] Experimental animals

[0080] Zebrafish were kept in aquaculture water at 28°C (water quality: 200 mg instant sea salt was added to 1 L of reverse osmosis water, conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / L CaCO 3 ), bred and provided by our company's fish farming center, the experimental animal use license number is: SYXK (Zhejiang) 2022-0004, the breeding and management complies with the requirements of the international AAALAC certification (certification number: 001458), IACUC ethics review number: IACUC-2023-5749-01.

[0081] Melanin allele mutant zebrafish (albino), transgenic vascular red fluorescent zebrafish, and wild-type AB strain zebrafish were bred in natural pairs. Zebrafish aged 5 dpf were used for MTC determination and efficacy evaluation of Tibetan Jinbao tablet candy in improving blood flow.

[0082] Instruments, consumables and reagents

[0083] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); precision electronic balance (CP214, OHAUS, USA); 6-well plate (Zhejiang Bellanbo Biotechnology Co., Ltd., China); motorized focus continuous zoom fluorescence microscope (AZ100, Nikon, Japan); heartbeat blood flow analyzer (ZebraBlood 3.4, ViewPoint Life Sciences, France).

[0084] Methylcellulose (Batch No. C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); dimethyl sulfoxide (DMSO, Batch No. BCCD8942, Sigma, Switzerland); Ponatinib (Batch No. 13771, mce, USA); o-dianisidine (Batch No. MKBX3619V, Sigma, USA); anhydrous sodium acetate (Batch No. F20090306, Sinopharm Chemical Reagent Co., Ltd., China); anhydrous ethanol (Batch No. G1726004, Shanghai Aladdin Biochemical Technology Co., Ltd., China).

[0085] Detection Methods

[0086] MTC assay

[0087] 5 dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). The water-soluble Tibetan Jinbao tablet candy (concentrations are shown in Table 4) was given separately, and the normal control group and model control group were set up at the same time, with a volume of 3 mL per well. Except for the normal control group, the other experimental groups were given ponatinib in water to establish the zebrafish endothelial vascular injury model. After 1 day of treatment at 28℃, the MTC of Tibetan Jinbao tablet candy on the model zebrafish was determined.

[0088] Evaluation of blood flow improvement efficacy (vessel diameter)

[0089] 5 dpf transgenic vascular red fluorescent zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). The Tibetan Jinbao tablet candy prepared in Example 1-3 and two comparative samples of ginseng negative and oat glucan negative were respectively given in water, with a concentration of 31.2 μg / mL of MTC, and a positive control aspirin concentration of 60.0 μg / mL. A normal control group and a model control group were set up at the same time, and the capacity of each well was 3 mL. Except for the normal control group, all other experimental groups were given ponatinib in water to establish a zebrafish endothelial vascular injury model. After 1 day of treatment at 28°C, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. The data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software, and the zebrafish vascular diameter was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of Tibetan Jinbao tablet candy in improving blood flow. The statistical processing results are expressed as mean ± SE. SPSS 26.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant.

[0090] Improve blood flow efficacy evaluation (blood flow velocity)

[0091] 5 dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). The Tibetan Jinbao tablet candy prepared in Example 1-3 and two comparison samples of ginseng negative and oat glucan negative were respectively given in water, with a concentration of 31.2 μg / mL of MTC and a positive control aspirin concentration of 60.0 μg / mL. A normal control group and a model control group were set up at the same time, and the capacity of each well was 3 mL. Except for the normal control group, all other experimental groups were given ponatinib in water to establish a zebrafish endothelial vascular injury model. After 1 day of treatment at 28°C, 10 zebrafish were randomly selected from each experimental group and placed in a heartbeat blood flow analysis system to detect the blood flow velocity of zebrafish. The statistical analysis results of this indicator were used to evaluate the efficacy of Tibetan Jinbao tablet candy in improving blood flow. The statistical treatment results are expressed as mean ± SE. SPSS26.0 software was used for statistical analysis, and p< 0.05 indicated that the difference was statistically significant.

[0092] Evaluation of blood flow improvement efficacy (cardiac red blood cell staining intensity)

[0093] 5 dpf melanin allele mutant zebrafish (albino) were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). The Tibetan Jinbao tablet candy prepared in Example 1-3 and two comparative samples of ginseng negative and oat glucan negative were respectively given in water, with a concentration of 31.2 μg / mL of MTC, and a positive control aspirin concentration of 60.0 μg / mL. A normal control group and a model control group were set up at the same time, and the capacity of each well was 3 mL. Except for the normal control group, all other experimental groups were given ponatinib in water to establish a zebrafish endothelial injury thrombosis model. After treatment at 28°C for 1 day, o-dianisidine staining was performed. After staining, 10 zebrafish were randomly selected from each experimental group and placed under a dissecting microscope for photography. The data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software, and the zebrafish heart red blood cell staining intensity was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of Tibetan Jinbao tablet candy in improving blood flow. The statistical results were expressed as mean ± SE. SPSS 26.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant.

[0094] Test results

[0095] MTC

[0096] Under the experimental conditions, the MTC of Tibetan Jinbao tablet candy in improving blood flow is 31.2 μg / mL. See Table 4 for details.

[0097] Table 4. Results of the experimental study on the concentration of Zangdi Jinbao tablet candy in improving blood flow (n = 30)

[0098]

[0099] Evaluation of blood flow improvement efficacy (vessel diameter)

[0100] Under the experimental conditions, Tibetan Jinbao tablet candy has the effect of significantly increasing the diameter of blood vessels, and the lack of ginseng (DB1) in the formula will significantly affect the effect of increasing the diameter of blood vessels. See Table 5 for details. Figure 7 to Figure 9 .

[0101] Table 5. Results of the evaluation experiment on the blood flow improvement effect (vascular diameter) of each group of samples (n = 10)

[0102] Group Concentration (µg / mL) Vessel diameter (pixels, mean ± SE) Normal control group (ZC) - 16.5 ± 0.589*** Model control group (MX) - 9.64 ± 0.188 Aspirin (ASPL) 60.0 14.1 ± 0.456*** Comparison group 1 (DB1) 31.2 10.9 ± 0.518*### Comparison Group 2 (DB2) 31.2 13.8 ± 0.245*** Experimental group (SYZ) 31.2 14.6 ± 0.615***

[0103] Compared with the model control group, ***p < 0.001; compared with the experimental group #p < 0.05, ##p < 0.01, ###p <0.001

[0104] Improve blood flow efficacy evaluation (blood flow velocity)

[0105] Under the experimental conditions, Tibetan Jinbao tablet candy has the effect of increasing blood flow velocity, and the ginseng in the formula has a significant effect on improving blood flow velocity, and the sufficient use of prebiotics (isomaltooligosaccharide and oat beta-glucan) also has a significant effect. See Table 6 for details. Fig.10 .

[0106] Table 6. Results of the evaluation experiment on the blood flow improvement effect (blood flow velocity) of each group of samples (n = 10)

[0107] Group Concentration (µg / mL) Blood flow velocity (μm / s, mean ± SE) Normal control group (ZC) - 1639 ± 39.6*** Model control group (MX) - 396 ± 45.7 Aspirin (ASPL) 60.0 595 ± 67.0* Comparison group 1 (DB1) 31.2 468 ± 38.2# Comparison Group 2 (DB2) 31.2 624 ± 77.2* Experimental group (SYZ) 31.2 632 ± 63.3**

[0108] Compared with the model control group, *p < 0.05, ***p < 0.001; compared with the experimental group, #p < 0.05, ##p < 0.01

[0109] Evaluation of blood flow improvement efficacy (cardiac red blood cell staining intensity)

[0110] Under the experimental conditions, Tibetan Jinbao tablet candy has a significant effect of increasing cardiac blood flow (increasing the intensity of cardiac red blood cell staining), and the lack of ginseng and oat glucan in the formula will significantly affect this improvement effect. See Table 7 for details. Figure 11 to Figure 13

[0111] Table 7. Results of the evaluation experiment on the blood flow improvement effect (cardiac red blood cell staining intensity) of each group of samples (n = 10)

[0112] Group Concentration (µg / mL) Cardiac erythrocyte staining intensity (pixels, mean ± SE) Normal control group (ZC) - 17035 ± 659*** Model control group (MX) - 5584 ± 274 Aspirin (ASPL) 60.0 7967 ± 200*** Comparison group 1 (DB1) 31.2 7461 ± 523**# Comparison Group 2 (DB2) 31.2 7485 ± 602* Experimental group (SYZ) 31.2 8859 ± 409***

[0113] Compared with the model control group, *p < 0.05, ***p < 0.001; compared with the experimental group, #p < 0.05, ##p < 0.01

[0114] Experimental summary: The raw materials used in Tibetan Jinbao tablet candy are all new resource foods or medicinal and edible sources. This experiment confirmed that the ginseng, natto powder, oat glucan and oligosaccharide in the formula have a certain synergistic effect, and the complete or partial absence of these raw materials will significantly affect its effect of improving vascular status.

Claims

1. A medicinal and edible composition for improving vascular status, characterized in that it comprises the following raw materials in parts by weight: 60-90 parts of isomaltooligosaccharide, 60-90 parts of hawthorn powder, 60-90 parts of ginseng powder, 40-70 parts of oat β-glucan, 40-70 parts of natto powder, 40-70 parts of bamboo leaf flavonoids, 10-30 parts of red yeast rice, and 10-30 parts of sea buckthorn powder.

2. The edible and medicinal composition according to claim 1, characterized in that it comprises the following raw materials in parts by weight: 80 parts of isomaltooligosaccharide, 66 parts of hawthorn powder, 62 parts of ginseng powder, 55 parts of oat β-glucan, 50 parts of natto powder, 45 parts of bamboo leaf flavonoids, 20 parts of red yeast rice, and 15 parts of sea buckthorn powder.

3. The medicine-food composition according to claim 2, characterized in that it also includes the following ingredients in parts by weight: 62 parts of pregelatinized starch, 37 parts of sorbitol, 5 parts of silicon dioxide, and 3 parts of magnesium stearate.

4. The edible and medicinal composition according to any one of claims 1 to 3, characterized in that the nattokinase content in the natto powder is greater than or equal to 30,000 FU / g.

5. The medicine-food composition according to any one of claims 1-4, characterized in that the improvement of vascular status includes assisting in lowering blood lipids and improving blood flow.

6. The edible and medicinal composition according to claim 5, characterized in that the auxiliary lipid-lowering effect is specifically manifested in reducing triglyceride content and cholesterol content; the blood flow improvement effect is specifically manifested in increasing blood vessel diameter, increasing blood flow velocity and increasing cardiac red blood cell staining intensity.

Images